The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.
Barbara A Conley,Lou Staudt,Naoko Takebe,David A Wheeler,Linghua Wang,Maria F Cardenas,Viktoriya Korchina,Jean Claude Zenklusen,Lisa M McShane,James V Tricoli,Paul M Williams,Irina Lubensky,Geraldine O'Sullivan-Coyne,Elise Kohn,Richard F Little,Jeffrey White,Shakun Malik,Lyndsay N Harris,Bhupinder Mann,Carol Weil,Roy Tarnuzzer,Chris Karlovich,Brian Rodgers,Lalitha Shankar,Paula M Jacobs,Tracy Nolan,Sean M Berryman,Julie Gastier-Foster,Jay Bowen,Kristen Leraas,Hui Shen,Peter W Laird,Manel Esteller,Vincent Miller,Adrienne Johnson,Elijah F Edmondson,Thomas J Giordano,Benjamin Kim,S Percy Ivy
DOI: https://doi.org/10.1093/jnci/djaa061
2021-01-01
Journal of the National Cancer Institute
Abstract:BACKGROUND:Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying exceptional responders retrospectively, obtaining pre-exceptional response treatment tumor tissues, and analyzing them with state-of-the-art molecular analysis tools to identify potential molecular explanations for responses.
METHODS:Exceptional response was defined as partial (PR) or complete (CR) response to a systemic treatment with population PR or CR rate less than 10% or an unusually long response (eg, duration >3 times published median). Cases proposed by patients' clinicians were reviewed by clinical and translational experts. Tumor and normal tissue (if possible) were profiled with whole exome sequencing and, if possible, targeted deep sequencing, RNA sequencing, methylation arrays, and immunohistochemistry. Potential germline mutations were tracked for relevance to disease.
RESULTS:Cases reflected a variety of tumors and standard and investigational treatments. Of 520 cases, 476 (91.5%) were accepted for further review, and 222 of 476 (46.6%) proposed cases met requirements as exceptional responders. Clinical data were obtained from 168 of 222 cases (75.7%). Tumor was provided from 130 of 168 cases (77.4%). Of 117 of the 130 (90.0%) cases with sufficient nucleic acids, 109 (93.2%) were successfully analyzed; 6 patients had potentially actionable germline mutations.
CONCLUSION:Exceptional responses occur with standard and investigational treatment. Retrospective identification of exceptional responders, accessioning, and sequencing of pretreatment archived tissue is feasible. Data from molecular analyses of tumors, particularly when combining results from patients who received similar treatments, may elucidate molecular bases for exceptional responses.